Lyell Immunopharma, Inc. capital & dividend

Leverage, liquidity, debt coverage and shareholder-distribution metrics.

Leverage

Debt / equity: 0.18x
Net debt / equity: -0.15x
Debt / assets: 0.14x
Debt / EBITDA: -0.20x
Net debt / EBITDA: 0.18x

Liquidity & coverage

Current ratio: 7.23x
Quick ratio: 7.23x
Cash ratio: 6.88x
Interest coverage: —
EBITDA / interest: —
Working capital: $230.4M

Cash & dividend

FCF / debt: -2.75x
Cash flow / debt: -2.74x
Dividend per share: —
Dividend yield: —
Dividend growth 1y: —

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.